Trial Profile

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled 26-Week Dose-Response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 19 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoglitazone (Primary) ; Pioglitazone
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Daiichi Sankyo Inc

Most Recent Events

06 Apr 2010 Results published in Current Medical Research and Opinion.
10 Sep 2007 Status changed from in progress to completed.
20 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com